Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-003 gene therapy study in Duchenne muscular dystrophy
2024-514501-57-00Phase 2Authorised
- Sponsor
- Solid Biosciences
- Start
- Jun 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of SGT-003 in Duchenne muscular dystrophy (DMD), sponsored by Solid Biosciences. Primary endpoints: Incidence of treatment-emergent adverse events and Change from baseline of microdystrophin protein levels. Planned start Jun 2025; status: authorised.
02
Drugs
SGT-003
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-514501-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514501-57-00.